healthy volunteers, Absorption, Distribution, Metabolism and Excretion (ADME) study with single oral administration of [14C] AZD8931
Study identifier:D0102C00007
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
[14C] AZD8931 - A Phase I, Open Label Study of the Absorption, Metabolism, Excretion, and Pharmacokinetics Following a Single Oral Dose to Healthy Male Subjects
Medical condition
Healthy
Phase
Phase 1
Healthy volunteers
Yes
Study drug
[14C] AZD8931
Sex
Male
Actual Enrollment
6
Study type
Interventional
Age
50 Years - 65 Years
Date
Study Start Date: 01 Mar 2011
Primary Completion Date: 01 May 2011
Study Completion Date: 01 May 2011
Study design
Allocation: N/A
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Other
Verification:
Verified 01 Aug 2014 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: AZD8931 [14C] AZD8931 | Drug: [14C] AZD8931 Single 160 mg oral dose administered on Day 1 |
Contacts
Investigators
Principal Investigator
Darren Wilbraham
Quintiles Drug Research Unit at Guy's Hospital
